Observational long-term follow-up (n=24) of participants from PSIL201 (psilocybin or niacin) using web surveys and telephone interviews over 24 months.
Long-term observational cohort follow-up of participants dosed in Study PSIL201; assessments conducted by a central site at months 2–6 (±7 days) and months 8, 10, 12, 14, 16, 18, 20, 22, and 24 (±14 days).
Data collection comprises web surveys and telephone interviews to capture clinical status and patient-reported outcomes; no investigational product is administered in this study.
Participants previously dosed with psilocybin in parent Study PSIL201; no new intervention administered in this follow-up.
No intervention administered as part of this follow-up; participants previously received psilocybin in Study PSIL201.
Participants previously dosed with niacin in parent Study PSIL201; no new intervention administered in this follow-up.
No intervention administered as part of this follow-up; participants previously received niacin in Study PSIL201.